Neovasc (NVCN) Reports Q3 Loss of $0.70, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Neovasc Announces Third Quarter 2018 Financial Results
November 14, 2018 4:00 PM ESTNASDAQ, TSX: NVCN
FDA has granted Breakthrough Device designation to the Neovasc Reducer (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany Tiara (the "Tiara") featured in live case at the 32nd Annual European Association for Cardio-Thoracic Surgery (EACTS) Meeting in Milan Peer-reviewed article on Tiara cases published in Circulation: Cardiovascular Interventions Regained compliance with the Nasdaq minimum bid price ruleVANCOUVER, Nov. 14, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX:... More
